"We are quadrupling our existing drug development and clinical research facilities," Kiran Mazumdar Shaw, MD, Biocon Ltd said at the sidelines of the India Economic Summit in New Delhi.
The company would not only expand its facilities but also plans to enter data management. Shaw said the company expects to sell insulin in the US and European markets in the two years.
She said it would take about two years to get permissions from the US Food and Drug Administration to export finished insulin to US.
"We expect our manufacturing facility to be inspected by the USFDA shortly and after the inspection, the realistic timeline to sell insulin in the US would be around 24 months," Shaw said.
The company currently has 12 new products in the pipeline including antibiotics, diabetes drug, cancer vaccines, and cardio-vascular drug among others.
It expects to launch a new anti-arthritis drug in the next 3-4 years in the Indian market, which could prove to be a multi-billion dollar opportunity for the company. Recently, the company had launched a new cancer drug and is optimistic about the revenues the drug would garner in the next 10 years.
© 2026